Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp (SLXN) filed a Form 8-K on January 6, 2026 under Item 7.01 (Regulation FD Disclosure) to announce a press release titled “Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026.” The company furnished the press release as Exhibit 99.1 to the filing, which the filing states is incorporated by reference.

Key Details

• Filing date: January 6, 2026 (Form 8-K, Item 7.01 - Regulation FD Disclosure).
• Press release title: “Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026.”
• The press release was furnished as Exhibit 99.1 to the Form 8-K.
• No new financial statements or earnings figures were reported in this filing.

Why It Matters
This 8-K provides management’s public update on 2025 accomplishments and the company’s near-term milestones for 2026, giving investors insight into strategic priorities and upcoming catalysts. Because the disclosure was made under Regulation FD and furnished as an exhibit, the information was broadly shared with the market; however, the filing does not include financial results or changes in personnel. Investors should review the CEO letter itself (Exhibit 99.1) for specifics on program progress, timelines, or operational goals that could affect SLXN’s outlook.